A Phase 3 interventional study of Alirocumab and Placebo in Atherosclerotic Cardiovascular Disease, sponsored by Sanofi. Completed at 1,388 sites in 57 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-03-18.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.
Among the 468 studies in Atherosclerosis with a site in United States, this one is the 3rd largest by enrollment of the 328 interventional ones that give a count, is one of 19 that started in 2012, is one of 61 in phase 3, and was the 243rd registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 55+
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
468 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 84 · Phase 3 74 · Phase 4 45
First in 1973; this study’s year is marked. 19 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18,924 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 119 across the 328 interventional studies, 170 across the 137 observational. Of the 366 that completed or were terminated, 134 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 468 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 8 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
23 of the studies in Atherosclerosis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07121010University of PittsburghHow Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 468 studies in Atherosclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia.
Secondary Objectives:
18924 number of participants aged >= 40 years old were randomized in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Recently (\< 52 weeks) hospitalized for ACS.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.
Drug: Placebo · Drug: LMT
Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels \>=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were \<25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were \<15 mg/dL (0.39 mmol/L).
Drug: Alirocumab · Drug: LMT
Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
Also known as: SAR236553, REGN727, Praluent®
Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study
All MACE positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the analysis of the composite cardiovascular (CV) outcome measure comprised of Coronary Heart Disease (CHD) death, non-fatal Myocardial Infarction (MI), fatal and non-fatal ischemic stroke (IS), or unstable angina (UA) requiring hospitalization. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of MACE over time. Percentage of observed participants with outcome measure events during the study were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study
All CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death, non-fatal non-fatal MI, UA requiring hospitalization, or ischemia-driven coronary revascularization procedure. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study
All Major CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death and non-fatal MI. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any major CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study
All CV events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CV endpoint comprised of any non-fatal CHD event, any CV death and non-fatal IS. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CV event over time. Percentage of observed participants with outcome measure events during the study were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study
All-cause mortality, non-fatal MI and non-fatal IS positively adjudicated by CEC in a blinded fashion, were used in the analysis of this endpoint. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of all-cause mortality, non-fatal MI and non-fatal IS over time. Percentage of observed participants with outcome measure events during the study were reported.
Time frame: From randomization up to 64 months
Time to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CHD death over time. Percentage of observed participants with CHD death (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Time to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CV death over time. Percentage of observed participants with CV death (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Time to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the all-cause death over time. Percentage of observed participants with all-cause death (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any non-fatal MI over time. Percentage of observed participants with any non-fatal MI (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of fatal or any non-fatal IS over time. Percentage of observed participants with fatal or any non-fatal IS (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any UA requiring hospitalization over time. Percentage of observed participants with any UA requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any ischemia-driven coronary revascularization procedure over time. Percentage of observed participants with any ischemia-driven coronary revascularization procedure (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Time to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHF requiring hospitalization over time. Percentage of observed participants with any CHF requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.
Time frame: From randomization up to 64 months
Percent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: ITT Analysis
Adjusted means and standard errors at Month 4, 12 and 48 from multiple imputation approach (to account for missing data) followed by analyses of covariance (ANCOVA) model with the fixed categorical effect of treatment group and the continuous fixed covariate of baseline LDL-C value, including all available post-baseline data from Month 1 up to Month 48 regardless of status on- or off-treatment.
Time frame: Baseline, Months 4, 12 and 48
Percent Change From Baseline in Calculated LDL-C at Months 4, 12, and 48: On-Treatment Analysis
Adjusted Least-squares (LS) means and standard errors at Month 4, 12 and 48 were obtained from a mixed-effect model with repeated measures (MMRM) including available post-baseline on-treatment data from Month 1 up to Month 48 (i.e. up to 21 days after last injection).
Time frame: Baseline, Months 4, 12 and 48
The study was conducted at 1387 sites in 57 countries. Of these, 1328 active sites randomized at least 1 participant. Overall, 35,437 participants were screened between 11 October 2012 and 17 Jan 2017; of whom 16,513 were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Started | 9462 | 9462 |
| Treated | 9443 | 9451 |
| Completed | 7947 | 7378 |
| Not completed | 1515 | 2084 |
| Withdrew: Randomized but not treated | 19 | 11 |
| Withdrew: Adverse event | 347 | 362 |
| Withdrew: Two consecutive ldl-c <15 mg/dl | 0 | 730 |
| Withdrew: Poor compliance to protocol | 529 | 454 |
| Withdrew: Physician decision | 77 | 62 |
| Withdrew: Site terminated by sponsor | 1 | 3 |
| Withdrew: Participant moved | 139 | 104 |
| Withdrew: Withdrawal by subject | 118 | 91 |
| Withdrew: Related to study drug administration | 96 | 105 |
| Withdrew: Lost to follow-up | 17 | 15 |
| Withdrew: Other than specified above | 172 | 147 |
All MACE positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the analysis of the composite cardiovascular (CV) outcome measure comprised of Coronary Heart Disease (CHD) death, non-fatal Myocardial Infarction (MI), fatal and non-fatal ischemic stroke (IS), or unstable angina (UA) requiring hospitalization. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of MACE over time. Percentage of observed participants with outcome measure events during the study were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study | 11.1 | 9.5 |
All CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death, non-fatal non-fatal MI, UA requiring hospitalization, or ischemia-driven coronary revascularization procedure. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study | 14.3 | 12.7 |
All Major CHD events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CHD endpoint comprised of any CHD death and non-fatal MI. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any major CHD event over time. Percentage of observed participants with outcome measure events during the study were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study | 9.5 | 8.4 |
All CV events positively adjudicated by CEC in a blinded fashion, were used in the analysis of the composite CV endpoint comprised of any non-fatal CHD event, any CV death and non-fatal IS. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CV event over time. Percentage of observed participants with outcome measure events during the study were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study | 15.6 | 13.7 |
All-cause mortality, non-fatal MI and non-fatal IS positively adjudicated by CEC in a blinded fashion, were used in the analysis of this endpoint. Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of all-cause mortality, non-fatal MI and non-fatal IS over time. Percentage of observed participants with outcome measure events during the study were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study | 11.9 | 10.3 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CHD death over time. Percentage of observed participants with CHD death (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study | 2.3 | 2.2 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the CV death over time. Percentage of observed participants with CV death (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study | 2.9 | 2.5 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the all-cause death over time. Percentage of observed participants with all-cause death (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study | 4.1 | 3.5 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any non-fatal MI over time. Percentage of observed participants with any non-fatal MI (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study | 7.6 | 6.6 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of fatal or any non-fatal IS over time. Percentage of observed participants with fatal or any non-fatal IS (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study | 1.6 | 1.2 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any UA requiring hospitalization over time. Percentage of observed participants with any UA requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study | 0.6 | 0.4 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any ischemia-driven coronary revascularization procedure over time. Percentage of observed participants with any ischemia-driven coronary revascularization procedure (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study | 8.8 | 7.7 |
Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the first occurrence of any CHF requiring hospitalization over time. Percentage of observed participants with any CHF requiring hospitalization (positively adjudicated by CEC in a blinded fashion) were reported.
| percentage of participants | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Time to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study | 1.9 | 1.9 |
Adjusted means and standard errors at Month 4, 12 and 48 from multiple imputation approach (to account for missing data) followed by analyses of covariance (ANCOVA) model with the fixed categorical effect of treatment group and the continuous fixed covariate of baseline LDL-C value, including all available post-baseline data from Month 1 up to Month 48 regardless of status on- or off-treatment.
| Percent change | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Month 4 | 4.4 ± 0.3 | -55.8 ± 0.3 |
| Month 12 | 8.0 ± 0.4 | -45.7 ± 0.4 |
| Month 48 | 16.4 ± 1.8 | -23.5 ± 1.6 |
Adjusted Least-squares (LS) means and standard errors at Month 4, 12 and 48 were obtained from a mixed-effect model with repeated measures (MMRM) including available post-baseline on-treatment data from Month 1 up to Month 48 (i.e. up to 21 days after last injection).
| Percent change | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W |
|---|---|---|
| Month 4 | 4.4 ± 0.3 | -58.3 ± 0.3 |
| Month 12 | 8.2 ± 0.4 | -52.8 ± 0.4 |
| Month 48 | 14.6 ± 1.0 | -40.1 ± 1.0 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form until the end of study (Month 64) regardless of seriousness or relationship to Investigational Medicinal Product (IMP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 278/9,443 (2.9%) | 2,350/9,443 (24.9%) | 2,181/9,443 (23.1%) |
| Alirocumab | 238/9,451 (2.5%) | 2,202/9,451 (23.3%) | 2,203/9,451 (23.3%) |
| Event | Placebo | Alirocumab |
|---|---|---|
| Non-Cardiac Chest PainGeneral disorders | 222/9443 | 219/9451 |
| Angina PectorisCardiac disorders | 133/9443 | 113/9451 |
| PneumoniaInfections and infestations | 108/9443 | 96/9451 |
| Atrial FibrillationCardiac disorders | 98/9443 | 82/9451 |
| SyncopeNervous system disorders | 73/9443 | 67/9451 |
| Acute Kidney InjuryRenal and urinary disorders | 62/9443 | 57/9451 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 51/9443 | 38/9451 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 46/9443 | 50/9451 |
| Peripheral Arterial Occlusive DiseaseVascular disorders | 47/9443 | 27/9451 |
| Sudden Cardiac DeathGeneral disorders | 42/9443 | 36/9451 |
| Event | Placebo | Alirocumab |
|---|---|---|
| HypertensionVascular disorders | 574/9443 | 542/9451 |
| NasopharyngitisInfections and infestations | 532/9443 | 567/9451 |
| MyalgiaMusculoskeletal and connective tissue disorders | 496/9443 | 522/9451 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 488/9443 | 457/9451 |
| Non-Cardiac Chest PainGeneral disorders | 462/9443 | 481/9451 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 58.6 ± 9.4 | 58.5 ± 9.3 | 58.6 ± 9.3 |
| Sex: Female, Male(Participants) | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Female | 2372 | 2390 | 4762 |
| Male | 7090 | 7072 | 14162 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 1555 | 1581 | 3136 |
| Not Hispanic or Latino | 7721 | 7700 | 15421 |
| Unknown or Not Reported | 186 | 181 | 367 |
| Race/Ethnicity, Customized(Participants) | Placebo | Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Total |
|---|---|---|---|
| White | 7524 | 7500 | 15024 |
| Black or African American | 238 | 235 | 473 |
| Asian | 1247 | 1251 | 2498 |
| Other | 449 | 469 | 918 |
| Unknown | 2 | 6 | 8 |
Showing the first 100 of 1,388 sites across 57 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2012 to primary completion in Jan 2018, 63 months.
Results were first posted in Mar 2019, 1 year 1 month after primary completion.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 63 months is above that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab